BioSpace News Archive

Dragonfly Therapeutics, Inc. (“Dragonfly” or the “Company”), today announced it has licensed another TriNKET™ immunotherapy drug candidate to Celgene Corporation and its affiliates (“Celgene”).

NEWTON, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2019 and provided an update on the Company’s recent corporate developments. “We have been very active as we continue to progress the development of

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the third quarter of 2019.

Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced its financial results for the third quarter ended September 30, 2019.

89bio, Inc. (Nasdaq: ETNB), today announced the closing of its upsized initial public offering of 6,100,390 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase up to 795,703 additional shares of common stock, at a public offering price of $16.00 per share.

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced third quarter 2019 financial results and provided an operational update.

Harrow Health, Inc. (NASDAQ: HROW) today reported results for the third quarter 2019.

GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in two upcoming investor conferences.

HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), a leading provider of health savings accounts (HSAs) and complementary consumer-directed benefits (“CDBs”), today announced its plans to release financial results for its third quarter of fiscal year 2020, following the close of regular stock market trading hours on Tuesday, December 3, 2019.

Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in the 31st Annual Piper Jaffray Healthcare Conference in New York.